EXPRS2 — ExpreS2ion Biotech Holding AB Share News
0.000.00%
Last trade - 00:00- SEK24.46m
- -SEK8.46m
- SEK12.21m
Brief: ExpreS2ion Biotech Holding Q1 Group Turnover At SEK 2.8 Million
Brief: Expres2ion Announces Bavarian Nordic Enters Agreement
Brief: ExpreS2ion Announces Last Part Of Loan Conversion And New Loan Facility
Brief: ExpreS2ion To Support COVID-19 Diagnostic Antibody Development Project
Brief: ExpreS2ion Announces Selection Of AGC Biologics As Manufacturing Partner For Covid-19 Vaccine; Provides Update To Program
Brief: ExpreS2ion Announces Loan Conversion
Brief: ExpreS2ion Announces SEK 6.7 Mln Grant For Development Influenza Vaccine
Brief: ExpreS2ion Rearranges Event Schedule Due To Coronavirus Restrictions
Brief: Expres2ion Announces EU Grant Award For The Covid-19 Vaccine Development Programme
Brief: Expres2ion Biotech Holding Q4 Pretax Loss Widens To SEK 6.9 Mln
Brief: Expres2ion Signs Option To License Agreement With Adaptvac Regarding Unique Breast Cancer Vaccine
Brief: ExpreS2ion's JV AdaptVac Receives Grant
Brief: Expres2ion To Lead European COVID-19 Vaccine Consortium For Rapid Clinical Development
Brief: ExpreS2ion JV AdaptVac Gets US Patent For Its Core Platform Technology
Brief: ExpreS2ion Appoints New CEO
Brief: ExpreS2ion Awarded SEK 2.7 Mln For Continued Development Of Two Malaria Vaccine Candidates
Brief: Expres2ion Biotech Q3 Pretax Loss Narrows To SEK 3.6 Mln
Brief: ExpreS2ion's JV AdaptVac Receives Danish Innobooster Grant Of SEK 1.2 Mln
Brief: ExpreS2ion Secures SEK 8 Million In Bridge Financing To Facilitate Further Growth